Valuation: Orion Oyj

Market Cap 11.48B 13.16B 10.84B 9.84B 18.44B 1,263B 18.52B 130B 50.1B 642B 49.44B 48.35B 2,066B P/E 2026 *
20.3x
P/E 2027 * 17.2x
Enterprise Value 11.39B 13.06B 10.75B 9.76B 18.29B 1,253B 18.37B 129B 49.7B 637B 49.06B 47.97B 2,050B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 4.69x
Free-Float
90.5%
Yield 2026 *
2.39%
Yield 2027 * 2.66%
1 week 63.4
Extreme 63.4
63.4
1 month 63.4
Extreme 63.4
63.4
3 years 52.69
Extreme 52.69
63.55
5 years 36
Extreme 36
63.55
10 years 24.85
Extreme 24.85
63.55
Manager TitleAgeSince
Chief Executive Officer 59 01/11/2022
Director of Finance/CFO 50 01/05/2024
Chief Operating Officer 46 01/01/2022
Director TitleAgeSince
Director/Board Member 63 22/03/2017
Director/Board Member 65 22/03/2017
Director/Board Member 66 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%0.00%+18.50% 13.16B
+0.04%+3.34%+53.32%+100.52% 1,028B
-0.09%+1.66%+53.24%+66.45% 651B
-0.02%+2.66%+18.65%+71.97% 466B
-1.22%+3.66%+34.59%+38.81% 346B
-0.79%+2.73%+17.73%+25.11% 266B
+0.58%+6.76%+10.58%+17.75% 259B
+1.55%+2.20%+35.12%+45.91% 208B
+0.79%+1.84%-27.55%-56.48% 191B
-0.52%+4.45%+31.57%+98.11% 186B
Average +0.04%+3.26%+22.72%+42.67% 400.19B
Weighted average by Cap. -0.04%+3.09%+34.72%+61.44%

Financials

2026 *2027 *
Net sales 2.1B 2.41B 1.98B 1.8B 3.37B 231B 3.38B 23.73B 9.16B 117B 9.04B 8.84B 378B 2.37B 2.72B 2.24B 2.04B 3.81B 261B 3.83B 26.85B 10.36B 133B 10.23B 10B 427B
Net income 566M 649M 534M 485M 909M 62.27B 913M 6.4B 2.47B 31.66B 2.44B 2.38B 102B 668M 766M 631M 573M 1.07B 73.5B 1.08B 7.55B 2.92B 37.37B 2.88B 2.81B 120B
Net Debt -89.76M -103M -84.75M -76.96M -144M -9.88B -145M -1.02B -392M -5.02B -387M -378M -16.16B -333M -382M -314M -285M -535M -36.64B -537M -3.77B -1.45B -18.63B -1.43B -1.4B -59.94B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
-
Date Price Change
18/09/26 €63.40 0.00%
17/09/26 €63.40 0.00%
16/09/26 €63.40 0.00%
15/09/26 €63.40 0.00%
14/09/26 €63.40 0.00%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
81.50EUR
Average target price
76.67EUR
Spread / Average Target
-5.93%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!